Hayley Virgil | Authors


Improved Survival Outcomes in Advanced RCC Seen with First-Line Immunotherapy, But Benefit Yet to Be Determined in Favorable-Risk Disease

September 16, 2021

While the benefit is yet to be determined in those with favorable-risk disease, patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib.

Adagrasib Reveals Efficacy in KRAS G12CMutated NSCLC

June 17, 2021

Updated findings from the early-stage KRYSTAL-1 study showed that treatment with adagrasib resulted in durable responses, broad disease control, and provided extensive predicted coverage throughout the dosing interval in patients with KRAS G12Cmutant advanced non–small cell lung cancer.

Responses Achieved With Zandelisib/Zanubrutinib in R/R CLL, B-Cell Lymphomas

June 14, 2021

A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.